orphan drug OligoG CF
orphan disease cystic fibrosis
treatment of CF
study drug
cystic fibrosis available
planned clinical trial
treatment of cystic fibrosis lung disease
European Clinical Trial Network
successful trial
CF patients
FDA Orphan Drug Designation
New Drug Application
set of clinical
pivotal phase IIb clinical trial of inhaled alginate oligosaccharide
standardised CF questionnaires
EU Orphan Drug Medicinal Product Designation
various effects of OligoG
improved therapeutic approach
lung function
European sites
finalized phase
Lung Clearance Index
European Medicines Agency
final study design
successful project
exploratory endpoints
disruption of bacterial biofilm
increased bacterial susceptibility
frequency of pulmonary exacerbations
LCI
measurements
release of stagnant mucus
preparation of international applications
non-culture-dependent microbiology
conditional marketing authorisation
infection status
cMAA
selection criteria
spirometry
coordination
protocol assistance
model systems
outcomes
procedures
current proposal
objective
scientific advice
work programme
antibiotics
CFQ-R
EMA
results
properties relevant
accordance
seaweed